Hikma Pharmaceuticals Plc
15 April 2008
Notice of Annual Report and Accounts
LONDON, 15 April 2008 - Hikma Pharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX:
HIK), the multinational pharmaceuticals group, announces that the Company's
Annual Report and Accounts for the year ending 31 December 2007 has been posted
to shareholders. A copy of the report can be found on the Company's website
(www.hikma.com) and on the DIFX website (www.difx.ae).
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Susan Ringdal +44 20 7399 2760
Investor Relations Director
Brunswick Group
Jon Coles / Justine McIlroy / +44 20 7404 5959
Alex Tweed
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: 'Branded', 'Injectables' and 'Generics'.
Hikma's operations are based principally in the Middle East and North Africa
('MENA') region, where it is a market leader and sells across 17 countries, the
United States and Europe. In 2007, the Group achieved revenues of $449 million
(2006 $317 million) and profit attributable to shareholders was $63 million
(2006 $55 million). For news and other information, please visit www.hikma.com.
This information is provided by RNS
The company news service from the London Stock Exchange